KYTHERA Biopharma prices upsized deal at $16, at high end of the range

By Renaissance Capital,

Shutterstock photo

KYTHERA Biopharmaceuticals, which is commercializing an injectable treatment for double chins with Bayer, raised $70 million by offering 4.4 million shares at $16, at high end of the range of $14 to $16. The 4.4 million shares offered was 10% more than originally anticipated. KYTHERA Biopharma plans to list on the NASDAQ under the symbol KYTH. J.P. Morgan and Goldman Sachs acted as lead managers on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines IPOs
Referenced Stocks: KYTH

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by